Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis

BMC Bioinformatics

Volumn 14, Issue SUPPL16, 2013, Pages

  Pennisi, Marzio ^a   Rajput, Abdul Mateen ^b,c   Toldo, Luca ^c   Pappalardo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BONN   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGENT-BASED MODEL; BALANCING MECHANISMS; CENTRAL NERVOUS SYSTEMS; CROSS REGULATION; ESSENTIAL DYNAMICS; GENETIC PREDISPOSITION; MULTIPLE SCLEROSIS; RELAPSING-REMITTING MULTIPLE SCLEROSIS;

CELL MEMBRANES;

PATHOLOGY;

ARTICLE; BIOLOGICAL MODEL; BRAIN; GENETIC PREDISPOSITION; HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; PATHOLOGY; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84886801709     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-14-S16-S9     Document Type: Article

References (58)

1. Compston A, McDonald I, Noseworthy J, Lassmann H, Miller D, Smith K, Wekerle H, Confavreux C. McAlpine's Multiple Sclerosis. Elsevier, 4, ISBN 9780443072710.
2. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, DeLuca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC. Expression of the Multiple Sclerosis-Associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D. PLoS Genet 2009, 5(2):e1000369. doi:10.1371/journal.pgen.1000369, 10.1371/journal.pgen.1000369, 2627899, 19197344.
3. Compston A, Coles A. Multiple Sclerosis. Lancet 2002, 359(9313):1221-1231. 10.1016/S0140-6736(02)08220-X, 11955556.
4. Willer CJ, Dyment DA, Risch NJ, Sadovick AD, Ebers GC. Twin Concordance and Sibling Recurrence Rates in Multiple Sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(22):12877-12882. 10.1073/pnas.1932604100, 240712, 14569025.
5. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ, Hankinson SE, Hunter DJ. Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: a Prospective Study. Journal of the American Medical Association 2001, 286(24):3083-3088. 10.1001/jama.286.24.3083, 11754673.
6. Ponsonby AL, van der Mei I, Dwyer T, Blizzard L, Taylor B, Kemp A, Simmons R, Kilpatrick T. Exposure to Infant Siblings During Early Life and Risk of Multiple Sclerosis. Journal of the American Medical Association 2005, 293(4):463-469. 10.1001/jama.293.4.463, 15671431.
7. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L. An Altered Immune Response to Epstein-Barr Virus in Multiple Sclerosis: a Prospective Study. it Neurology 2004, 62(12):2277-2282.
8. Goodin DS. The Causal Cascade to Multiple Sclerosis: A Model for MS Pathogenesis. PLoS ONE 2009, 4(2):e4565. doi:10.1371/journal.pone.0004565, 10.1371/journal.pone.0004565, 2644781, 19242548.
9. Huynh JL, Casaccia P. Epigenetic Mechanisms in Multiple Sclerosis: Implications for Pathogenesis and Treatment. The Lancet Neurology 2013, 12(2):195-206. doi:10.1016/S1474-4422(12)70309-5.
10. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001, 22(2):117-139. 10.1007/s100720170011, 11603614.
11. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747. 10.1146/annurev.immunol.23.021704.115707, 15771584.
12. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The Natural History of Multiple Sclerosis: a Geographically Based Study 9: Observations on the Progressive Phase of the Disease. Brain 2006, 129(3):584-594. 10.1093/brain/awh721, 16401620.
13. Vélez de Mendizábal N, Carneiro J, Solé RV, Goñi J, Bragard J, Martinez-Forero I, Martinez-Pasamar S, Sepulcre J, Torrealdea J, Bagnato F, Garcia-Ojalvo J, Villoslada P. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis. BMC Systems Biology 2011, 5:114. 10.1186/1752-0509-5-114, 3155504, 21762505., http://www.biomedcentral.com/1752-0509/5/114
14. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early Onset Multiple Sclerosis: a Longitudinal Study. Neurology 2002, 59(7):1006-1010. 10.1212/WNL.59.7.1006, 12370453.
15. Steinman L. Multiple Sclerosis: a Two-stage Disease. Nature Immunology 2001, 2(9):762-764. 10.1038/ni0901-762, 11526378.
16. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Current Opinion in Neurology 1999, 12(3):295-302. 10.1097/00019052-199906000-00008, 10499174.
17. Fontenot JD, Rudensky AY. A Well Adapted Regulatory Contrivance: Regulatory T Cell Development and the Forkhead Family Transcription Factor Foxp3. Nature Immunology 2005, 6(4):331-337. 10.1038/ni1179, 15785758.
18. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells. Science 2008, 320(5880):1220-1224. 10.1126/science.1155209, 2519146, 18436744.
19. Carneiro J, Leon K, Caramalho I, van den Dool C, Gardner R, Oliveira V, Bergman ML, Sepúlveda N, Paixão T, Faro J, Demengeot J. When Three Is Not a Crowd: a Crossregulation Model of the Dynamics and Repertoire Selection of Regulatory CD4+ T Cells. Immunological Reviews 2007, 216:48-68.
20. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alphachains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155(3):1151-1164.
21. Motta S, Pappalardo F. Mathematical modeling of biological systems. Briefings in Bioinformatics 2012, doi:10.1093/bib/bbs061.
22. Read M, Andrews PS, Timmis J, Kumar V. Techniques for grounding agent-based simulations in the real domain: a case study in experimental autoimmune encephalomyelitis. Mathematical and Computer Modelling of Dynamical Systems: Methods, Tools and Applications in Engineering and Related Sciences 2012, 18:1. 67-86.
23. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188(2):287-296. 10.1084/jem.188.2.287, 2212461, 9670041.
24. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007, 8(12):1353-1362. 10.1038/ni1536, 17982458.
25. Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003, 198(2):249-258. 10.1084/jem.20030315, 2194065, 12874258.
26. Lünemann JD, Kamradt T, Martin R, Münz C. Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?. J Virol 2007, 81(13):6777. 10.1128/JVI.00153-07, 1933281, 17459939.
27. Christensen JR, Börnsen L, Khademi M, Olsson T, Jensen PE, Sørensen PS, Sellebjerg F. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler 2013, 19(7):877-884. 10.1177/1352458512466929, 23178691.
28. Hillert J, Olerup O. HLA and MS. Neurology 2004, 43:2426-2427.
29. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18-32. 10.1034/j.1600-065X.2001.1820102.x, 11722621.
30. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188(2):287-296. 10.1084/jem.188.2.287, 2212461, 9670041.
31. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164(1):183-190.
32. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001, 182:58-67. 10.1034/j.1600-065X.2001.1820104.x, 11722623.
33. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006, 212:8-27. 10.1111/j.0105-2896.2006.00427.x, 16903903.
34. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005, 6(4):331-337. 10.1038/ni1179, 15785758.
35. Van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007, 2007:89017. 2248278, 18317533.
36. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007, 38(1-3):112-121. 10.1007/s12026-007-0022-2, 17917016.
37. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. JExpMed 2004, 199(7):971-979.
38. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109(1):131-140. 150819, 11781358.
39. Guo Z, Han HK, Tay JC. Sufficiency verification of HIV-1 pathogenesis based on multi-agent simulation. Proc of the ACM Genetic and Evolutionary Computation Conference (GECCO'05) 2005, 305-312.
40. Perrin D, Ruskin HJ, Burns J, Crane M. An agent-based approach to immune modelling. Lecture Notes in Computer Science 2006, 3980:612-621.
41. Bernaschi M, Castiglione F. Design and implementation of an immune system simulator. Comp in Biol and Med 2001, 3:303-331.
42. Pappalardo F, Lollini P-L, Castiglione F, Motta S. Modelling and simulation of cancer immuno-prevention vaccine. Bioinformatics 2005, 21:2891-2897. 10.1093/bioinformatics/bti426, 15817697.
43. Pennisi M, Pappalardo M, Palladini A, Nicoletti G, Nanni P, Lollini P-L, Motta S. Modeling the competition between lung metastases and the immune system using agents. BMC Bioinformatics 2010, 11(Suppl 7):S13. 10.1186/1471-2105-11-S7-S13, 3040527, 21210980.
44. Palladini A, Nicoletti G, Pappalardo F, Murgo A, Grosso V, Stivani V, Ianzano ML, Antognoli A, Croci S, Landuzzi L, De Giovanni C, Nanni P, Motta S, Lollini P-L. In silico modeling and in vivo efficacy of cancer preventive vaccinations. Cancer Research 2010, 70:7755-7763. 10.1158/0008-5472.CAN-10-0701, 20924100.
45. Pappalardo F, Cincotti A, Motta S, Pennisi M. Agent based modeling of atherosclerosis: a concrete help in personalized treatments. Lecture Notes in Artificial Intelligence 2009, 5755:386-396.
46. Elizabeth S. NetLogo, a multi-agent simulation environment. Artificial Life 2011, 13(3):303-311.
47. Pennisi M, Catanuto R, Pappalardo F, Motta S. Optimal vaccination schedules using simulated annealing. Bioinformatics 2008, 24(15):1740-1743. 10.1093/bioinformatics/btn260, 18535084.
48. Pappalardo F, Mastriani E, Lollini PL, Motta S. Genetic algorithm against cancer. LNCS 2006, 3849:223-228.
49. Pappalardo F, Forero IM, Pennisi M, Palazon A, Melero I, Motta S. SimB16: Modeling induced immune system response against B16-melanoma. PLoS ONE 2011, 6(10):e26523. 10.1371/journal.pone.0026523, 3197530, 22028894.
50. Pennisi M, Pappalardo F, Motta S. Agent based modeling of lung metastasis-immune system competition. LNCS 2009, 5666:1-3.
51. Alemani D, Pappalardo F, Pennisi M, Motta S, Brusic V. Combining cellular automata and lattice Boltzmann method to model multi scale vascular timor growth coupled with nutrient diffusion and immune competition. Journal of Immunological Methods 2012, 376(1-2):55-68. 10.1016/j.jim.2011.11.009, 22154892.
52. Pappalardo F, Pennisi M, Motta S. Universal Immune System Simulator framework (UISS). Proceedings of the First ACM International Conference on Bioinformatics and Computational Biology (ACM-BCB 2010) 2010, 649-650.
53. Yoav S, Leyton-Brown K. Multiagent Systems: Algorithmic, Game-Theoretic, and Logical Foundations. Cambridge University Press 2009, 504. ISBN 978-0-521-89943-7.
54. Wu Y, Zhu WQ. Stochastic analysis of a pulse-type prey-predator model. Phys Rev E Stat Nonlin Soft Matter Phys 2008, 77(4 Pt 1):041911.
55. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006, 24:571-606. 10.1146/annurev.immunol.23.021704.115601, 16551260.
56. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L. An altered immune response to Epstein-Barr virus in multiple sclerosis A prospective study. NEUROLOGY 2004, 62:2277-2282. 10.1212/01.WNL.0000130496.51156.D7, 15210894.
57. Trandem K, Anghelina D, Zhao J, Perlman S. Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus. Journal of immunology 2010, 184(8):4391-4400.
58. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435(7042):590-597. 10.1038/nature03724, 15931211.